SITE002-0202

SITE002 (USA) › SITE002-0202

SITE002-0202

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-05-06

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 111); relationship: not assessed

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 72); relationship: NOT RELATED

moderate assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 53); relationship: not assessed

severe assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 42); relationship: not assessed

moderate assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 24); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.